Subclinical myasthenia gravis causing increased sensitivity to botulinum toxin therapy.
In rare patients receiving botulinum toxin (BT) therapy the potency of the BT drug may be increased by pre-existent impairment of neuromuscular transmission (INT). Appropriate dose adjustment may correct for this. Subclinical INT has previously been described by us for the first time in a patient with Lambert-Eaton myasthenic syndrome. We are now describing subclinical INT for the first time in a patient with ocular myasthenia gravis. Due to its unpredictability subclinical INT may pose a risk to patients receiving BT therapy.
Dressler
Dirk
D
Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. dressler.dirk@mh-hannover.de
D000368:Aged; D019274:Botulinum Toxins, Type A / Q000009:adverse effects*; D005260:Female; D006801:Humans; D018908:Muscle Weakness / Q000139:chemically induced*; D009157:Myasthenia Gravis / Q000150:complications* / Q000503:physiopathology; D014103:Torticollis / Q000150:complications* / Q000188:drug therapy*
D019274:Botulinum Toxins, Type A